Navigation Links
Ospedale Niguarda Ca' Granda-Milano Adopts Latest Technology to Treat Patients with Heart Failure
Date:8/5/2008

Orqis(R) Medical Reports Impressive Result in Hospitalized Patient

SCHAFFHAUSEN, Switzerland, Aug. 6 /PRNewswire/ -- Orqis(R) International GmbH, a medical products company marketing devices to treat heart failure, announced first use of the Cancion(R) System on May 27 by Dr. Maria Frigerio and Dr. Fabrizio Oliva at Ospedale Niguarda Ca' Granda-Milano, Milano, Italy, as part of the hospital's objective to provide the latest medical technology to treat patients.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080806/LAW519LOGO)

Dr. Frigerio and Dr. Oliva successfully treated a patient hospitalized with heart failure who was not responding to optimized medical management. Treatment with the Cancion System improved the patient's health to the point where the patient was successfully discharged home after being hospitalized for six months (since December 2007). Remarkably, he has remained out of the hospital over 65 days for any heart failure-related conditions.

The Cancion System enables aortic flow therapy which provides physicians with a low-risk tool to improve cardiac performance and unload the heart -- without touching the heart. The catheter-based, percutaneous device addresses patients suffering from acute decompensated heart failure by moving blood from an iliac artery to the descending aorta through the use of an extracorporeal circulatory support. This proprietary therapy uniquely bridges the treatment gap between medical management and more invasive procedures -- without ever touching the heart.

"There has been very little progress in creating effective new approaches for treating patients with heart failure," stated Dr. Frigerio. She continued, "The Cancion System provides Ospedale Niguarda Ca' Granda-Milano with the latest technology so we may provide the best care for our patients."

Laura Eaton, R.N., Director, U.S. Sales, Orqis Medical stated, "Use of the Cancion System in this patient demonstrates the compelling hemodynamic benefit of aortic flow therapy." She continued, "The Cancion System provides physicians with a viable new option to treat heart failure patients from a course of decline to a course of improvement."

The Cancion System is distributed in Italy by NGC Medical spa (http://www.ngc.it).

About Heart Failure

Heart failure is a condition in which the heart becomes weakened and cannot pump blood efficiently. Heart failure is caused by coronary artery disease, past myocardial infarctions, cardiomyopathy and other underlying cardiovascular disorders, and it is characterized by shortness of breath, functional impairment, and edema.

About Orqis International GmbH

Orqis is a privately held medical device company that develops and sells minimally invasive devices that improve cardiac performance through aortic flow therapy. Orqis devices uniquely bridge the treatment gap between medical management and more invasive procedures without ever touching the heart. The percutaneous Cancion System bears the CE mark of conformity, and the implantable Exeleras(R) System is in development.

For more information on Orqis Medical, please visit http://www.orqis.ch

Note: Orqis(R), Cancion(R), and Exeleras(R) are registered trademarks of Orqis Medical Corporation.


'/>"/>
SOURCE Orqis International GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. AMA Adopts Strategies to Help Address Medical Student Debt
2. AMA Adopts New Public Health Policies at Annual Meeting
3. AMA Adopts New Policies at Annual Meeting
4. SyntheMed, Inc. Adopts Shareholder Rights Plan
5. Haemonetics Chairman and CEO Adopts 10b5-1 Stock Trading Plan
6. Virginias largest Cardiac Surgery program adopts SPY as standard of care
7. Edwards Lifesciences Chairman and CEO Adopts New 10b5-1 Stock Trading Plan to Replace Recently Expired Plan
8. Indiana Adopts Legislation to Combat Illegitimate Online Pharmacies, Protect Residents From Counterfeit Drugs
9. Weight Watchers COO Adopts 10b5-1 Trading Plan
10. Masimo Corporation Adopts Stockholder Rights Plan
11. APHA Adopts New Policies on Food Safety, Global Climate Change, Multidrug-Resistant Organisms, Breastfeeding and Feminine Hygiene
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SAN FRANCISCO, Calif. , June 24, 2016 ... GBT ), a biopharmaceutical company developing novel therapeutics ... significant unmet needs, today announced the closing of ... shares of common stock, at the public offering ... shares in the offering were offered by GBT. ...
(Date:6/24/2016)... BEIJING , June 24, 2016 Dehaier ... or the "Company"), which develops, markets and sells medical ... China , signed a strategic cooperation agreement with ... as "Hongyuan Supply Chain") on June 20, 2016, to ... Under the strategic cooperation agreement, Dehaier will leverage Hongyuan ...
(Date:6/24/2016)... Belgium , June 24, 2016 /PRNewswire/ ... announced the appointment of Dr. Edward Futcher ... a Non-Executive Director, effective June 23, 2016.Dr. Futcher ... and Nominations and Governance Committees.  As a non-executive ... provide independent expertise and strategic counsel to VolitionRx ...
Breaking Medicine Technology: